Bortezomib for Acute Humoral Rejection Treatment at the Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán in Mexico City: An Update.
Leyva S, Marino LA, Alberú J, Morales-Buenrostro LE.
Clinical Transplants 2010, Chapter 35
The use of bortezomib as a treatment modality of AHR improved and stabilized graft function (clinical response) in the majority of patients. Its use in single dose, even combined with rituximab, does not seem to be useful to obtain a sustained clinical response, or to reduce HLAabs level. The use of 4 doses of bortezomib in days 1, 4, 7, and 10 (1.3 mg/m2 BSA each) plus plasmapheresis produced both a good clinical response and a reduction in DSA. Moving forward, it will be necessary to define the long-term effectiveness of bortezomib and whether rituximab administration is indispensable to achieve this goal. Until now, it is evident that many patients needed retreatment and they were well tolerated.